Literature DB >> 11713941

Hepatitis C virus (HCV) RNA determination after two weeks of induction interferon treatment is an accurate predictor of nonresponse: comparison of two treatment schedules.

A Rossini1, M Artini, M Levrero, C Almerighi, M Massari, L Biasi, E Radaeli, E Cariani.   

Abstract

The aim of this study was to analyze of HCV kinetics during interferon treatment administered daily or three times weekly. Seventy-seven naive patients were randomized to two treatment courses starting with four weeks of high-dose interferon administered daily or three times weekly. Twenty-two patients (28.6%) achieved end-of-treatment response and nine (11.7%, four of whom received daily induction) sustained response. The initial decline of viral load was sharper in patients receiving daily induction, but the rates of early RNA clearance were independent of treatment schedule, being higher in patients with genotype non-1. Detectable HCV RNA during treatment predicted nonresponse more significantly than high pretreatment viral load or genotype 1. HCV RNA at week 2 was the best predictor (100% sensitivity in patients receiving daily induction). In conclusion, daily induction increased the HCV decline slope, but not the rate of virological response. HCV RNA at week 2 reliably identified nonresponders.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11713941     DOI: 10.1023/a:1012303315214

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  16 in total

1.  Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

Authors:  A U Neumann; N P Lam; H Dahari; D R Gretch; T E Wiley; T J Layden; A S Perelson
Journal:  Science       Date:  1998-10-02       Impact factor: 47.728

2.  Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa.

Authors:  S Zeuzem; J H Lee; A Franke; B Rüster; O Prümmer; G Herrmann; W K Roth
Journal:  Hepatology       Date:  1998-04       Impact factor: 17.425

3.  Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa.

Authors:  N P Lam; A U Neumann; D R Gretch; T E Wiley; A S Perelson; T J Layden
Journal:  Hepatology       Date:  1997-07       Impact factor: 17.425

Review 4.  Factors predictive of a beneficial response to therapy of hepatitis C.

Authors:  G L Davis; J Y Lau
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

Review 5.  Early predictors of response to treatment in patients with chronic hepatitis C.

Authors:  M P Civeira; J Prieto
Journal:  J Hepatol       Date:  1999       Impact factor: 25.083

6.  Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C.

Authors:  B Gavier; M A Martínez-González; J I Riezu-Boj; J J Lasarte; N Garcia; M P Civeira; J Prieto
Journal:  Gastroenterology       Date:  1997-11       Impact factor: 22.682

7.  Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C.

Authors:  M Buti; G Olive; C Stalgis; R Esteban; J Guardi
Journal:  Dig Dis Sci       Date:  2000-04       Impact factor: 3.199

8.  Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group.

Authors:  W M Lee; K R Reddy; M J Tong; M Black; D J van Leeuwen; F B Hollinger; K D Mullen; N Pimstone; D Albert; S Gardner
Journal:  Hepatology       Date:  1998-11       Impact factor: 17.425

9.  Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.

Authors:  S Zeuzem; J M Schmidt; J H Lee; M von Wagner; G Teuber; W K Roth
Journal:  Hepatology       Date:  1998-07       Impact factor: 17.425

10.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

View more
  3 in total

1.  Interferon-alpha2b induction treatment with or without ribavirin in chronic hepatitis C: a multicenter, randomized, controlled trial.

Authors:  Hakan Senturk; Galip Ersoz; Resat Ozaras; Sabahattin Kaymakoglu; Hakan Bozkaya; Meral Akdogan; Ali Mert; Mithat Bozdayi; Fehmi Tabak; Necati Yenice; Gulsen Ozbay
Journal:  Dig Dis Sci       Date:  2003-06       Impact factor: 3.199

2.  Kinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naïve genotype 1 patients.

Authors:  Denis Ouzan; Hacène Khiri; Guillaume Pénaranda; Hélène Joly; Philippe Halfon
Journal:  Comp Hepatol       Date:  2005-12-21

3.  Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus.

Authors:  Eisuke Miyaki; Nobuhiko Hiraga; Michio Imamura; Takuro Uchida; Hiromi Kan; Masataka Tsuge; Hiromi Abe-Chayama; C Nelson Hayes; Grace Naswa Makokha; Masahiro Serikawa; Hiroshi Aikata; Hidenori Ochi; Yuji Ishida; Chise Tateno; Hideki Ohdan; Kazuaki Chayama
Journal:  PLoS One       Date:  2017-03-02       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.